137 related articles for article (PubMed ID: 33483163)
1. OFCC1-ALK (Ointergenic: A20): A novel OFCC1 intergenic region-ALK fusion identified from a lung adenocarcinoma patient.
Zhai X; Wu Q; Zeng Z; Suo J; Lin F; Zhou Q
Lung Cancer; 2021 Mar; 153():171-173. PubMed ID: 33483163
[No Abstract] [Full Text] [Related]
2. A Novel Intergenic Region Between KLHL31 and LRRC1-ALK Exon 20 Fusion Variant in Advanced Lung Adenocarcinoma and its Remarkable Response to ALK Inhibitor.
Qiu H; Li Q; Xiao Y; Wu D; Meng R
J Thorac Oncol; 2021 Apr; 16(4):e21-e23. PubMed ID: 33781445
[No Abstract] [Full Text] [Related]
3. HIP1-ALK, a novel fusion protein identified in lung adenocarcinoma.
Hong M; Kim RN; Song JY; Choi SJ; Oh E; Lira ME; Mao M; Takeuchi K; Han J; Kim J; Choi YL
J Thorac Oncol; 2014 Mar; 9(3):419-22. PubMed ID: 24518094
[TBL] [Abstract][Full Text] [Related]
4. [Detection of ALK, ROS1 and RET fusion genes in non-small cell lung cancer patients and its clinicopathologic correlation].
Zhong S; Zhang H; Bai D; Gao D; Zheng J; Ding Y
Zhonghua Bing Li Xue Za Zhi; 2015 Sep; 44(9):639-43. PubMed ID: 26705279
[TBL] [Abstract][Full Text] [Related]
5. Distribution and therapeutic outcomes of intergenic sequence-ALK fusion and coexisting ALK fusions in lung adenocarcinoma patients.
Cai C; Tang Y; Li Y; Chen Y; Tian P; Wang Y; Gong Y; Peng F; Zhang Y; Yu M; Wang K; Zhu J; Lu Y; Huang M
Lung Cancer; 2021 Feb; 152():104-108. PubMed ID: 33444901
[TBL] [Abstract][Full Text] [Related]
6. A novel EML4-ALK BIRC6-ALK double fusion variant in lung adenocarcinoma confers sensitivity to alectinib.
Zhong JM; Zhang GF; Lin L; Li DY; Liu ZH
Lung Cancer; 2020 Jul; 145():211-212. PubMed ID: 32409002
[No Abstract] [Full Text] [Related]
7. Coexistence of a novel RGS18 downstream intergenic region ALK fusion and a THUMPD2-ALK fusion in a lung adenocarcinoma patient and response to crizotinib.
Wang YL; Wu ZZ; Zhang HR; Chen DS; Zhao X
Lung Cancer; 2021 Apr; 154():216-218. PubMed ID: 33637344
[No Abstract] [Full Text] [Related]
8. PARD3-ALK: A novel ALK fusion gene identified in a patient with lung adenocarcinoma.
Yang L; Zhao W; Zhu H; Li X; Zhao G
Lung Cancer; 2021 Apr; 154():219-220. PubMed ID: 33676770
[No Abstract] [Full Text] [Related]
9. An intergenic region ALK fusion identified by DNA sequencing and validated by IHC in an early-stage lung adenocarcinoma.
Dou Y; Duan Q; Qi C; Hou L; Wang H
J Cancer Res Clin Oncol; 2021 Jun; 147(6):1865-1867. PubMed ID: 33544200
[TBL] [Abstract][Full Text] [Related]
10. Detection of ALK rearrangement by immunohistochemistry in lung adenocarcinoma and the identification of a novel EML4-ALK variant.
To KF; Tong JH; Yeung KS; Lung RW; Law PP; Chau SL; Kang W; Tong CY; Chow C; Chan AW; Leung LK; Mok TS
J Thorac Oncol; 2013 Jul; 8(7):883-91. PubMed ID: 23625156
[TBL] [Abstract][Full Text] [Related]
11. Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.
Ou SH; Klempner SJ; Greenbowe JR; Azada M; Schrock AB; Ali SM; Ross JS; Stephens PJ; Miller VA
J Thorac Oncol; 2014 Dec; 9(12):1821-5. PubMed ID: 25393796
[TBL] [Abstract][Full Text] [Related]
12. ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity.
Kimura H; Nakajima T; Takeuchi K; Soda M; Mano H; Iizasa T; Matsui Y; Yoshino M; Shingyoji M; Itakura M; Itami M; Ikebe D; Yokoi S; Kageyama H; Ohira M; Nakagawara A
Lung Cancer; 2012 Jan; 75(1):66-72. PubMed ID: 21757253
[TBL] [Abstract][Full Text] [Related]
13. DNA and RNA sequencing revealed a complex intergenic-ALK fusion in a lung adenocarcinoma patient who responded to TKI therapy.
Zhang J; Huang J; Li Q; Lin H; Luo Z; Chen R
Lung Cancer; 2021 Sep; 159():171-174. PubMed ID: 34266695
[No Abstract] [Full Text] [Related]
14. A novel KIF5B-ALK variant in nonsmall cell lung cancer.
Wong DW; Leung EL; Wong SK; Tin VP; Sihoe AD; Cheng LC; Au JS; Chung LP; Wong MP
Cancer; 2011 Jun; 117(12):2709-18. PubMed ID: 21656749
[TBL] [Abstract][Full Text] [Related]
15. [Clinical features of 54 cases of lung adenocarcinomas with c-ROS oncogene 1 fusion].
Cao H; Zheng J; Zhao J; Guo XJ; Zhou JY; Ding W; Zhou JY
Zhonghua Jie He He Hu Xi Za Zhi; 2020 Feb; 43(2):120-125. PubMed ID: 32062881
[No Abstract] [Full Text] [Related]
16. PLB1-ALK: A novel head-to-head fusion gene identified by next-generation sequencing in a lung adenocarcinoma patient.
Wang B; Chen R; Wang C; Chen H; Zhong D
Lung Cancer; 2021 Mar; 153():176-178. PubMed ID: 33483162
[No Abstract] [Full Text] [Related]
17. New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer.
Dubey AP; Pathi N; Viswanath S; Rathore A; Pathak A; Sud R
Indian J Cancer; 2017; 54(1):203-208. PubMed ID: 29199691
[TBL] [Abstract][Full Text] [Related]
18. Use of capture-based next-generation sequencing to detect ALK fusion in plasma cell-free DNA of patients with non-small-cell lung cancer.
Cui S; Zhang W; Xiong L; Pan F; Niu Y; Chu T; Wang H; Zhao Y; Jiang L
Oncotarget; 2017 Jan; 8(2):2771-2780. PubMed ID: 27926526
[TBL] [Abstract][Full Text] [Related]
19. Next-generation Sequencing Identified a Novel WDPCP-ALK Fusion Sensitive to Crizotinib in Lung Adenocarcinoma.
He Z; Wu X; Ma S; Zhang C; Zhang Z; Wang S; Yu S; Wang Q
Clin Lung Cancer; 2019 Sep; 20(5):e548-e551. PubMed ID: 31281052
[No Abstract] [Full Text] [Related]
20. Is Retention of the 5' Nononcogenic ALK Fusion Variant a Novel Poor Prognostic Factor in ALK-Positive NSCLC?
Hsiao SJ; Ou SI
J Thorac Oncol; 2020 Jul; 15(7):1103-1105. PubMed ID: 32593442
[No Abstract] [Full Text] [Related]
[Next] [New Search]
